论文部分内容阅读
组蛋白的去乙酰化是造成HIV潜伏感染的主要影响因素之一.目前,开发潜在的组蛋白去乙酰化酶抑制剂用以清除HIV病毒潜伏库,是人们重要的研究方向.MS275是苯胺酸类的组蛋白去乙酰化酶抑制剂,已经被批准应用于临床抗肿瘤实验,但其是否具有抗HIV潜伏治疗作用仍未见报道.本研究以HIV-1潜伏细胞株A7为模型,通过流式细胞技术检测MS275药物的不同浓度、作用时间对HIV-1潜伏诱导激活效率的影响;通过CCK-8方法检测药物对HEK293及Jurkat细胞的毒性作用.结果显示,MS275化合物对HIV-1潜伏细胞具有激活作用,并表现出剂量和时间效应关系;与SAHA相比,MS275对细胞毒性更低.本研究提示MS275有望成为抗HIV-1潜伏治疗的候选药物.
Histone deacetylation is one of the main factors that cause latent infection of HIV.At present, it is an important research direction to develop potential histone deacetylase inhibitors to clear latent library of HIV virus.MS275 is aniline Histone deacetylase inhibitor has been approved for clinical anti-tumor experiments, but whether it has the potential anti-HIV treatment has not been reported.In this study, a HIV-1 latent cell line A7 was used as a model, The cytotoxicity of drugs on HEK293 and Jurkat cells was detected by CCK-8 assay, and the cytotoxicity of MS275 on latent HIV-1-induced activation of HIV-1 cells MS275 has lower cytotoxicity than SAHA.The study suggests that MS275 is expected to become a potential drug candidate for anti-HIV-1 latent therapy.